title: A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome.
abstract: Immunosuppression with antithymocyte globulin (ATG) or cyclosporine (CSA) can be used to treat the cytopenia associated with myelodysplastic syndrome (MDS). Previously, we identified HLA-DR15, younger age, and shorter duration of red cell transfusion dependence as pretreatment variables that correlate significantly with a response. Using these pretreatment variables we have devised a simple method to prospectively identify patients with low or high probabilities of response to immunosuppression. The ability of this system to predict response was confirmed in a separate cohort of 23 patients with MDS treated with immunosuppression.
authors.affiliation: University of Illinois at Chicago, MBRB rm3150 (MC734), 900 S Ashland Ave, Chicago, IL 60607,USA. yogen@uic.edu
authors.forename: Yogen
authors.initials: Y
authors.lastname: Saunthararajah
authors.forename: Ryotaro
authors.initials: R
authors.lastname: Nakamura
authors.forename: Robert
authors.initials: R
authors.lastname: Wesley
authors.forename: Qiong J
authors.initials: QJ
authors.lastname: Wang
authors.forename: A John
authors.initials: AJ
authors.lastname: Barrett
mesh_terms: D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D015331:Cohort Studies; D016572:Cyclosporine / Q000627:therapeutic use; D006684:HLA-DR Antigens / Q000097:blood; D059810:HLA-DR Serological Subtypes; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016015:Logistic Models; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000961:Antilymphocyte Serum; D006684:HLA-DR Antigens; D059810:HLA-DR Serological Subtypes; C106559:HLA-DR15 antigen; D007166:Immunosuppressive Agents; D016572:Cyclosporine